A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Study Summary

This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.

Conditions

Colorectal Cancer Stage II Colorectal Cancer Stage III

Interventions / Drugs

RO7198457 intravenous (IV)Observational group (no intervention)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment327 participants

Primary Completion—

Lead SponsorBioNTech SE

Data Retrieved2026-04-11 02:55:25.057455+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.